Bio News
U.S.-based Enveda Biosciences raised $311 million in a Series E financing. Catalio Capital Management led the round, with 16 investors participating, including Surveyor Capital, T. Rowe Price and Lux Capital.
Enveda will use the funds to continue developing three clinical-stage drug candidates in immunology and obesity.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
